PharmaTelevision - Biosceptre: A New Approach to Cancer Research

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biosceptre: A New Approach to Cancer Research

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Alan Bootes, Chairman of Biosceptre International Ltd.

Filmed at AusBiotech 2009, they discuss:

• Biosceptre's unconventional approach to cancer
• the patents involved in Biosceptre's work
• partnering with other firms
• Alan's future hopes for Biosceptre's Biomarker

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Biosceptre's unconventional approach to cancer.

Fintan Walton:

Hello and welcome to Pharmatelevision news review here in Melbourne Australia. On this show I have Alan Bootes who is chairman of Biosceptre International Ltd based in Sydney Australia, welcome to the show.

Alan Bootes:

Thank you very much Fintan Walton.

Fintan Walton:

Biosceptre is a biotech company it's a privately held company, what sets Biosceptre apart from other companies in the biotech sector?

Alan Bootes:

We are in the immunological field looking at oncology solutions through immunological approaches that put us in with several hundred perhaps a thousand other small biotech's around the world. What sets Biosceptre apart is the is the approach we are taking, conventional wisdom and the path that most companies are following is based on the philosophy that every cancer is different and people are studying in great and greater detail the individual characteristics of like of each cancer type to understand how they differ from each other, then looking for a target and enter that target building antibodies and looking for diagnostics or treatment modalities that's the conventional approach. Biosceptre scientists stumbled upon something which has a potential to stand up whole concept of personalized medicine, targeted medicine on a tip. They have discovered a single cancer marker which is being this observed on every single type of cancer observed so far and that's some I think different sort of cancer so there are many others out there but the point is we have never looked yet at cancer tissue which has not exhibited this particular marker and the company has been engaged for the last eight to nine years in developing a range of antibodies which uniquely bind to that marker and not to any other types of marker or any other type of cells.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Alan Bootes
Chairman
Biosceptre International Ltd

Biosceptre International Ltd

Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia that is developing and commercializing antibody technologies to address a wide range of applications in the diagnosis and treatment of cancer.